9results about How to "Improve glucose tolerance" patented technology

The invention belongs to the technical field of biological medicines, discloses application of bifidobacterium breve BB990 in the field of metabolism, and particularly discloses bifidobacterium breve BB990 which is preserved in Guangdong Microorganism Culture Collection Center, the preservation number is GDMCC No.63259, and the preservation date is March 10, 2023. The invention further discloses a preparation method of the bifidobacterium breve BB990. The bifidobacterium breve BB990 provided by the invention has the effects of regulating gastrointestinal disorder, enhancing intestinal immune function, inhibiting harmful bacteria, improving intestinal flora structure, maintaining intestinal steady state, regulating immunity, improving immune curative effect, regulating body glycometabolism and liver metabolism and the like. Experiments prove that the bifidobacterium breve BB990 can effectively prevent and treat metabolic diseases, such as non-alcoholic fatty liver, type II diabetes and the like, the treatment effect of the bifidobacterium breve BB990 is remarkably superior to that of other bifidobacterium breve (such as bifidobacterium breve 206), and the bifidobacterium breve BB990 has a good prospect.

The invention discloses application of N-acetyl serotonin in preparation of a medicine for treating type 2 diabetes mellitus, and belongs to the field of biological medicine. In-vivo and in-vitro experiments prove that the N-acetyl serotonin can promote secretion of GLP-1, has the effects of obviously reducing blood sugar, being good in sugar tolerance and insulin tolerance, and is obviously improved aiming at high fasting blood glucose, high postprandial blood glucose, poor glucose tolerance and reduced insulin tolerance; the GLP-1 secretion insufficiency is obviously improved. The invention is of great significance in maintaining blood sugar stability and improving glucose and insulin tolerance of diabetic patients, and provides a new solution for treatment of type 2 diabetes mellitus.

The present invention relates to a novel plant lactobacillus strain and a composition for preventing or treating metabolic diseases comprising the strain. According to the plant lactobacillus strain (preservation number KCTC 14107BP) of the present invention, fat accumulation in white adipose tissue, brown adipose tissue and liver tissue can be effectively inhibited. The plant lactobacillus strain shows an excellent blood sugar improvement effect, particularly can reduce fasting blood sugar level. The plant lactobacillus strain can improve glucose tolerance and increase insulin sensitivity, thereby effectively improving insulin resistance. In addition, the plant lactobacillus strain can control the concentration of metabolic hormones in the blood. Therefore, the plant lactobacillus strain can be usefully used to prevent or treat metabolic diseases.

The present invention belongs to the field of biomedicine technology, and relates to a new use of the proteasome inhibitor ixazomib in pharmaceutical manufacturing, and specifically relates to the use of the proteasome inhibitor ixazomib in the preparation of a drug for treating diabetes, wherein the drug category is a drug for improving insulin resistance in type 2 diabetes, reducing fasting blood sugar, reducing random blood sugar, reducing glycosylated hemoglobin, reducing blood lipids, or improving glucose tolerance. The present invention also provides a method for improving insulin resistance in cells in vitro, and a diabetes drug with ixazomib as an active ingredient provides a new tool and approach for the treatment of diabetes. The tissue chip treated with ixazomib in the present invention provides a series of gene targets related to diabetes, which provides a basis for subsequent research and drug screening.

The invention discloses application of a small molecule peptide LKLKLL in preparation of a hypoglycemic product and application of the small molecule peptide LKLKLL in preparation of the hypoglycemic product. Experiments prove that the small molecule peptide LKLKLL can effectively reduce the blood sugar level and remarkably improve insulin resistance, and a brand new target is provided for treatment of type 2 diabetes mellitus. The small molecule peptide has a unique action mechanism in the aspect of reducing blood sugar, helps a patient to better manage the blood sugar level, and provides a solution for diabetes treatment.

The invention relates to the technical field of traditional Chinese medicine, in particular to compound essential oil for intervening obesity and application. The compound essential oil for intervening obesity comprises the following components in parts by weight: 8-30 parts of agilawood essential oil; the first component comprises rhizoma cyperi essential oil and ginger essential oil; the second component comprises pericarpium citri reticulatae essential oil, pericarpium citri reticulatae viride essential oil, pericarpium zanthoxyli essential oil, rhizoma atractylodis essential oil and fructus aurantii essential oil; the mass ratio of the agilawood essential oil to the first component to the second component is 3: 3: 10. Under the guidance of the traditional Chinese medicine aromatherapy theory, the compatibility of the traditional Chinese medicine essential oil in the related research is adjusted and improved, and through the synergistic interaction between the agilawood and the common formula components, the obvious treatment effect on obesity is achieved.

The invention relates to the technical field of microorganisms, in particular to application of Zymomonas mobilis ZM4 to improvement of diabetes mellitus, which comprises the following steps: performing liquid culture, centrifugation and resuspension on the Zymomonas mobilis ZM4 with the preservation number of ATCC31821 to obtain a bacterial suspension, and then using the bacterial suspension to improve the diabetes mellitus, wherein the Zymomonas mobilis ZM4 in the bacterial suspension still has activity after being centrifuged and resuspended; the bacterial suspension does not contain a fermentation product of the Zymomonas mobilis ZM4. According to the application of the Zymomonas mobilis ZM4 in improvement of diabetes mellitus, the probiotic characteristics of the Zymomonas mobilis ZM4 are utilized to improve the types and abundance of intestinal flora, so that the blood sugar of a mouse with type II diabetes mellitus is reduced, the oral glucose tolerance of the mouse is improved, the contents of glycosylated hemoglobin, blood insulin and GLP-1 are adjusted, and the diabetes mellitus is improved. The level of inflammatory factors related to diabetes mellitus is reduced, and damaged islet cells can be improved and recovered to a certain extent.

The application discloses a polysaccharide with lipid-lowering and weight-reducing effects, and a preparation method and application thereof. The polysaccharide is obtained by extracting a crude extract from plant raw materials and performing multi-stage separation and purification, and has a single component with lipid-lowering and weight-reducing effects. The polysaccharide can reduce or control weight gain, reduce fat content or lipid load, improve or restore liver morphology, inhibit or reduce liver weight gain, inhibit or reverse liver steatosis, improve sugar and lipid metabolism, improve intestinal flora structure and the like.

The application belongs to the technical field of biological medicine, and particularly relates to Lactobacillus murinus MF26 and application thereof in prevention and treatment of heart failure. The preservation number of the Lactobacillus murinus MF26 is CCTCC NO: M 20251548, and the preservation organization is China Center for Type Culture Collection (CCTCC). The Lactobacillus murinus MF26 can significantly improve left ventricular diastolic dysfunction of HFpEF mice, reduce myocardial fibrosis, relieve high blood pressure, significantly improve intestinal barrier permeability, reduce the inflammation level of the organism, and significantly increase the GLP-1 level in serum, thereby effectively improving the fasting blood glucose level and glucose tolerance of the HFpEF mice. Therefore, the Lactobacillus murinus MF26 can be used for preparing a drug or a functional food for preventing, relieving or / and treating the heart failure with preserved ejection fraction.